ES2382041T3 - Partículas de hidroxiapatita de emisión alfa y beta - Google Patents

Partículas de hidroxiapatita de emisión alfa y beta Download PDF

Info

Publication number: ES2382041T3
Authority: ES; Spain
Prior art keywords: hydroxyapatite; alpha; use according; treatment; radionuclide
Prior art date: 2004-02-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES05708405T

Other languages

English (en)

Spanish (es)

Inventor

Gro Salberg

Roy Larsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer AS

Original Assignee

Algeta ASA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-20

Filing date

2005-02-18

Publication date

2012-06-04

2005-02-18 Application filed by Algeta ASA filed Critical Algeta ASA

2005-02-18 Priority claimed from PCT/GB2005/000616 external-priority patent/WO2005079867A2/en

2012-06-04 Application granted granted Critical

2012-06-04 Publication of ES2382041T3 publication Critical patent/ES2382041T3/es

2025-02-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims abstract description 112
229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 108
239000002245 particle Substances 0.000 title description 32
239000000203 mixture Substances 0.000 claims abstract description 50
238000011282 treatment Methods 0.000 claims abstract description 45
201000010099 disease Diseases 0.000 claims abstract description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
206010028980 Neoplasm Diseases 0.000 claims description 31
WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 claims description 25
JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 claims description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
238000002560 therapeutic procedure Methods 0.000 claims description 6
230000002601 intratumoral effect Effects 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
238000001356 surgical procedure Methods 0.000 claims description 5
150000001768 cations Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
-1 polyethylenedones Substances 0.000 claims description 4
102000008186 Collagen Human genes 0.000 claims description 3
108010035532 Collagen Proteins 0.000 claims description 3
108010010803 Gelatin Proteins 0.000 claims description 3
230000036770 blood supply Effects 0.000 claims description 3
229920001436 collagen Polymers 0.000 claims description 3
229920000159 gelatin Polymers 0.000 claims description 3
239000008273 gelatin Substances 0.000 claims description 3
235000019322 gelatine Nutrition 0.000 claims description 3
235000011852 gelatine desserts Nutrition 0.000 claims description 3
206010061289 metastatic neoplasm Diseases 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
230000001954 sterilising effect Effects 0.000 claims description 3
229920001661 Chitosan Polymers 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
229910052797 bismuth Inorganic materials 0.000 claims description 2
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
239000002241 glass-ceramic Substances 0.000 claims description 2
GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 claims description 2
239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 2
229920000747 poly(lactic acid) Polymers 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
238000004659 sterilization and disinfection Methods 0.000 claims description 2
230000000118 anti-neoplastic effect Effects 0.000 claims 3
MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
229910052788 barium Inorganic materials 0.000 claims 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
229910052791 calcium Inorganic materials 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229910052746 lanthanum Inorganic materials 0.000 claims 1
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims 1
229910052712 strontium Inorganic materials 0.000 claims 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 1
229910052719 titanium Inorganic materials 0.000 claims 1
239000010936 titanium Substances 0.000 claims 1
229910052727 yttrium Inorganic materials 0.000 claims 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract description 36
238000001727 in vivo Methods 0.000 abstract description 18
230000015572 biosynthetic process Effects 0.000 abstract description 4
210000001519 tissue Anatomy 0.000 description 21
239000000243 solution Substances 0.000 description 16
230000000694 effects Effects 0.000 description 11
239000007788 liquid Substances 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
239000013049 sediment Substances 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
238000009826 distribution Methods 0.000 description 8
239000011347 resin Substances 0.000 description 8
229920005989 resin Polymers 0.000 description 8
230000008901 benefit Effects 0.000 description 7
239000000919 ceramic Substances 0.000 description 7
238000002648 combination therapy Methods 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000001802 infusion Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
239000000825 pharmaceutical preparation Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
239000011230 binding agent Substances 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
239000000084 colloidal system Substances 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
230000001613 neoplastic effect Effects 0.000 description 6
230000005855 radiation Effects 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
238000002372 labelling Methods 0.000 description 4
229910017604 nitric acid Inorganic materials 0.000 description 4
239000000047 product Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
238000004062 sedimentation Methods 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
206010019695 Hepatic neoplasm Diseases 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
230000005262 alpha decay Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
208000014018 liver neoplasm Diseases 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000003439 radiotherapeutic effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
ZSLUVFAKFWKJRC-AHCXROLUSA-N thorium-228 Chemical compound [228Th] ZSLUVFAKFWKJRC-AHCXROLUSA-N 0.000 description 3
229940122361 Bisphosphonate Drugs 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
208000005228 Pericardial Effusion Diseases 0.000 description 2
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
150000004663 bisphosphonates Chemical class 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
239000006071 cream Substances 0.000 description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
208000024407 malignant pericardial mesothelioma Diseases 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000003607 modifier Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
201000004266 pericardial mesothelioma Diseases 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
208000023958 prostate neoplasm Diseases 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
208000000649 small cell carcinoma Diseases 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
150000003990 18-crown-6 derivatives Chemical class 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
206010006002 Bone pain Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000282324 Felis Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027540 Microcytosis Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
206010070627 Tumour rupture Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
229910052768 actinide Inorganic materials 0.000 description 1
150000001255 actinides Chemical class 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
230000005255 beta decay Effects 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000004568 cement Substances 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
201000002660 colon sarcoma Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005188 flotation Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
238000001730 gamma-ray spectroscopy Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229910052732 germanium Inorganic materials 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
239000001307 helium Substances 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000005389 magnetism Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000000683 nonmetastatic effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000011362 radionuclide therapy Methods 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000011450 sequencing therapy Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000013112 stability test Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229920005613 synthetic organic polymer Polymers 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Optics & Photonics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Dispersion Chemistry (AREA)
Engineering & Computer Science (AREA)
Nanotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Confectionery (AREA)

ES05708405T 2004-02-20 2005-02-18 Partículas de hidroxiapatita de emisión alfa y beta Expired - Lifetime ES2382041T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0403856.8A GB0403856D0 (en)	2004-02-20	2004-02-20	Composition
GB0403856		2004-02-20
PCT/GB2005/000616 WO2005079867A2 (en)	2004-02-20	2005-02-18	Alpha-emitting hydroxyapatite particles

Publications (1)

Publication Number	Publication Date
ES2382041T3 true ES2382041T3 (es)	2012-06-04

Family

ID=32040119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES05708405T Expired - Lifetime ES2382041T3 (es)	2004-02-20	2005-02-18	Partículas de hidroxiapatita de emisión alfa y beta

Country Status (13)

Country	Link
JP (1)	JP5214884B2 (de)
KR (2)	KR20070038030A (de)
CN (1)	CN1972720B (de)
AT (1)	ATE544492T1 (de)
DK (1)	DK1735013T3 (de)
ES (1)	ES2382041T3 (de)
GB (1)	GB0403856D0 (de)
IL (1)	IL177354A (de)
NO (1)	NO20064232L (de)
NZ (1)	NZ549080A (de)
PT (1)	PT1735013E (de)
TW (1)	TWI347194B (de)
ZA (1)	ZA200606728B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO3111959T3 (de) *	2015-07-03	2018-02-10
US20170065731A1 (en) *	2015-09-06	2017-03-09	Medical Theranostics Inc.	Method, Apparatus, and System for Radiation Therapy
CN106344927A (zh) *	2016-09-27	2017-01-25	大连理工大学	叶酸修饰的载药羟基磷灰石及其制备方法
MX2023002801A (es) *	2020-09-15	2023-04-21	Oncoinvent As	Particulas radiomarcadas de tama?o controlado.
EP4646235A1 (de) *	2023-01-05	2025-11-12	Oncoinvent AS	Alpha-emittierende radionuklide zur verwendung bei der behandlung von peritonealkarzinom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE168015T1 (de) *	1990-12-21	1998-07-15	Mallinckrodt Medical Inc	Zur strahlensynovektomie nützliche radionukleotidmarkierte teilchen
WO1995011694A1 (en) *	1993-10-26	1995-05-04	Thomas Jefferson University	Compositions that specifically bind to colorectal cancer cells and methods of using the same
WO1997001304A1 (en) *	1995-06-29	1997-01-16	Mallinckrodt Medical, Inc.	Radiolabeled apatite particles containing a paramagnetic ion
CZ293919B6 (cs) *	1999-10-18	2004-08-18	Ferxáincorporated	Prostředek schopný reagovat na magnetické pole
JP3836444B2 (ja) *	2002-05-30	2006-10-25	独立行政法人科学技術振興機構	ハイドロキシアパタイト複合体およびその製造方法、ならびに、それを用いた医療用材料

2004
- 2004-02-20 GB GBGB0403856.8A patent/GB0403856D0/en not_active Ceased
2005
- 2005-02-18 PT PT05708405T patent/PT1735013E/pt unknown
- 2005-02-18 DK DK05708405.5T patent/DK1735013T3/da active
- 2005-02-18 KR KR1020067019354A patent/KR20070038030A/ko not_active Ceased
- 2005-02-18 ES ES05708405T patent/ES2382041T3/es not_active Expired - Lifetime
- 2005-02-18 ZA ZA200606728A patent/ZA200606728B/xx unknown
- 2005-02-18 CN CN2005800124785A patent/CN1972720B/zh not_active Expired - Fee Related
- 2005-02-18 AT AT05708405T patent/ATE544492T1/de active
- 2005-02-18 KR KR1020107009801A patent/KR101165518B1/ko not_active Expired - Fee Related
- 2005-02-18 TW TW094104922A patent/TWI347194B/zh not_active IP Right Cessation
- 2005-02-18 NZ NZ549080A patent/NZ549080A/en not_active IP Right Cessation
- 2005-02-18 JP JP2006553676A patent/JP5214884B2/ja not_active Expired - Fee Related
2006
- 2006-08-08 IL IL177354A patent/IL177354A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064232A patent/NO20064232L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20064232L (no)	2006-09-19
JP2007528373A (ja)	2007-10-11
NZ549080A (en)	2011-01-28
GB0403856D0 (en)	2004-03-24
TW200536558A (en)	2005-11-16
CN1972720B (zh)	2010-07-07
KR20100060029A (ko)	2010-06-04
CN1972720A (zh)	2007-05-30
DK1735013T3 (da)	2012-05-21
ZA200606728B (en)	2007-12-27
TWI347194B (en)	2011-08-21
JP5214884B2 (ja)	2013-06-19
KR20070038030A (ko)	2007-04-09
KR101165518B1 (ko)	2012-07-16
IL177354A0 (en)	2006-12-10
PT1735013E (pt)	2012-05-08
IL177354A (en)	2013-04-30
ATE544492T1 (de)	2012-02-15

Publication	Publication Date	Title
CA2555435C (en)	2011-07-12	Alpha-emitting hydroxyapatite particles
ES2247069T3 (es)	2006-03-01	Liposomas terapeuticos radioactivos.
ES2250419T3 (es)	2006-04-16	Radioterapia.
ES2649985T3 (es)	2018-01-16	Partículas y suspensiones radioterapéuticas
ES2424844T3 (es)	2013-10-09	Liposomas que encierran un radionucleido y doxorubicina para terapia de combinación
CN112843260B (zh)	2021-11-09	一种医用放射性二氧化硅微球及其制备方法与应用
US10918746B2 (en)	2021-02-16	Radioactive compositions and methods for their therapeutic use
Alkandari et al.	2023	Radiopharmaceutical encapsulated liposomes as a novel radiotracer Im-aging and drug delivery protocol
KR101165518B1 (ko)	2012-07-16	알파-방출 히드록시아파타이트 입자
Häfeli et al.	1997	Magnetically targeted microspheres for intracavitary and intraspinal Y-90 radiotherapy
EP3011977A1 (de)	2016-04-27	Kit zur herstellung von 186/188-rhenium markierten liposomen und ihre therapeutische anwendungen
Vimalnath et al.	2017	Formulation, characterization and bio-evaluation of Holmium-166 labeled agglomerated iron oxide nanoparticles for treatment of arthritis of knee joints
MXPA06009375A (en)	2007-04-10	Alpha-emitting hydroxyapatite particles
JP2007528373A5 (de)	2008-04-03
Klaassen et al.	2019	The various therapeutic applications of the medical isotope holmium-166: a narrative
Bao	2003	Development and use of technetium-99, rhenium-186 and rhenium-188-labeled liposomes for nuclear imaging and radionuclide therapy
HK1232446B (en)	2018-06-22	Radiotherapeutic particles and suspensions